Alnylam’s heart beats stronger
A win in Apollo-B should open up the multi-billion cardiomyopathy market, but questions remain.
Roche deal fails to Repare the licensing scene
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.
Alnylam shoots for the heart
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
Biotech catalysts on the horizon
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Bridgebio pushes forward with limb girdle project
Early data are encouraging, but with the biotech market still terrible investors need a lot more to get excited.
SFNP 2022 – Alnylam takes heart from its Onpattro follow-on
But further data do not shed much light on Onpattro’s chances in Apollo-B.
